Editorials

Time for Change in the Conduct of Clinical Trials in Patients with Rheumatoid Arthritis J.M. Kremer .......................... 2087

The Wisdom of the PHAROS S.C. Mathai ................................ 2089

An Added Perspective on the 2009 SPARTAN and IGAS Report: An Innate Axial Myofascial Hypertonicity A.T. Masi .................................................. 2092

Review


Articles

Baseline Numbers of Circulating CD28-negative T Cells May Predict Clinical Response to Abatacept in Patients with RA M. Scarsi, T. Ziglioli, P. Airo’ ............................................. 2105

Natural Killer-22 Cells in the Synovial Fluid of Patients with RA Are an Innate Source of IL-22 and TNF-α J. Ren, Z. Feng, Z. Lv, X. Chen, J. Li .............................................. 2112

CGS 21680, an Agonist of the Adenosine (A2A) Receptor, Reduces Progression of Murine Type II Collagen-induced Arthritis E. Mazzon, E. Esposito, D. Impellizzeri, et al ....................... 2119

Preferential Association of IRF5 Gene Variants with Seronegative RA in 2 Swedish Case-Control Studies C. Wang, H. Kokkonen, J.K. Sandling, et al .................................. 2130


NSAID Withdrawal in Patients with Stable RA G.E. McKellar, R. Hampson, A. Tierney, H.A. Capell, R. Madhok .......................................................... 2150

Serum Hecpicin: A Direct Link Between Anemia of Inflammation and Coronary Artery Atherosclerosis in Patients with RA M.A. Abdel-Khalek, A.M. El-Barbary, S.A-M. Essa, A.S. Ghabashi .................................................. 2153

Absent “Window of Opportunity” in Smokers with Short Disease Duration. Data from BARFOT, a Multicenter Study of Early RA M.K. Söderlin, S. Bergman, for the BARFOT Study Group .................................................. 2160

TCZ Monotherapy Reduces Arterial Stiffness as Effectively as Etanercept or Adalimumab Monotherapy in RA: An Open-label RCT K. Kume, K. Amano, S. Yamada, K. Hatta, H. Ohta, N. Kuwaba .................................................. 2169

Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study Population M. Hinchcliff, A. Fischer, E. Schiopu, V.D. Sleen ...................... 2172

Primary Biliary Cirrhosis-related Autoantibodies in a Large Cohort of Italian Patients with SSc I. Cavazzana, A. Ceribelli, M. Taraborrelli, et al .................................. 2180

Effect of Bosentan on SSc-associated Interstitial Lung Disease Ineligible for CYC Therapy: A Prospective Open-label Study Y. Furuya, M. Kuwana .................................................. 2186

Serum IL-9 Levels Are Increased in Patients with SSc: Association with Lower Frequency and Severity of Pulmonary Fibrosis K. Yanaba, A. Yoshizaki, Y. Asano, T. Kadono, S. Sato .................................................. 2193


HBV Reactivation by Immunosuppressive Therapy in Patients with Autoimmune Diseases: Risk Analysis in HBsAg-negative Cases M. Kato, T. Atsumi, T. Kurita, et al .................................. 2209


Incidence of TB Among Korean Patients with AS Who Are Taking TNF Blockers E-M. Kim, W-S. Uhm, S-C. Bae, D-H. Yoo, T-H. Kim .................................................. 2218


Quality of Nonpharmacological Care in the Community for People with Knee and Hip OA L.C. Li, E.C. Sayre, J.A. Kopec, J.M. Esdaile, S. Bar, J. Cibere .................................................. 2230
